CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

Monoclonal antibodies targeting CD38 are important for treatment of both newly diagnosed and relapsed multiple myeloma (MM). Daratumumab and isatuximab are anti-CD38 antibodies with the US Food and Drugs Administration approval in multiple different combinations. Despite good initial efficacy, patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez de Acha, Olivia, Reiman, Lauren, Jayabalan, David S., Walker, Zachary J., Bosma, Grace, Keller, Alana L., Parzych, Sarah E., Abbott, Diana, Idler, Beau M., Ribadeneyra, Drew, Niesvizky, Ruben, Forsberg, Peter A., Mark, Tomer M., Sherbenou, Daniel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598487/
https://www.ncbi.nlm.nih.gov/pubmed/37648670
http://dx.doi.org/10.1182/bloodadvances.2023010162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598487/
https://www.ncbi.nlm.nih.gov/pubmed/37648670
http://dx.doi.org/10.1182/bloodadvances.2023010162

Ejemplares similares